Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Inflection Pharma Consulting ApS
APS
Dissolved
CVR 39685507
C.N. Petersens Vej 11
Engineering activities and related technical consultancy · NACE 7112
Est. 2018
— employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2021
DKK -2K
-104% vs 2020
EBITDA margin
100.0%
-104% vs 2020
Equity ratio
82.4%
Financial strength
Net profit 2021
DKK -12K
-133% vs 2020
EBITDA — year on year
DKK millions
0M
0M
1M
1M
1M
0M
2018
0M
0%
2019
0M
0%
2020
0M
0%
2021
Key figures
Annual report 2021
Revenue
DKK -2K
-104%
EBITDA
DKK -2K
-104%
Net profit
DKK -12K
-133%
Total assets
DKK 114K
-19%
Equity
DKK 94K
-21%
Employees
—
—
Company information
Legal name
Inflection Pharma Consulting ApS
CVR number
39685507
Legal form
Anpartsselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
27. juni 2018
Share capital
DKK 41.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en direktør.
Contact
Address
C.N. Petersens Vej 11
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Engineering activities and related technical consultancy
Companies in Frederiksberg
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
0M
2018
0M
2019
0M
2020
0M
2021
EBITDA
DKK millions
0M
0M
1M
1M
1M
0M
2018
0M
2019
0M
2020
0M
2021
Income statement
DKK thousands
Item
2018
2019
2020
2021
Revenue
64
36
47
-2
Staff expenses
-0
-0
-0
-0
EBITDA
64
36
47
-2
Depreciation & amort.
-0
-0
-0
-0
EBIT
64
36
47
-2
Net financials
0
0
0
-1
Profit before tax
64
36
47
-3
Tax
14
9
11
9
Net profit
49
28
36
-12
Balance sheet
DKK thousands
Item
2018
2019
2020
2021
Total assets
81
106
141
114
Equity
54
82
118
94
Long-term debt
0
0
0
0
Short-term debt
27
24
23
20
Total debt
27
24
23
20
Financial ratios
5-year trend
EBITDA margin
-183200.0%
This company
15.8%
Market median
-1159594% vs market
2018
2021
Equity ratio
82.4%
This company
38.2%
Market median
+116% vs market
2018
2021
Return on equity
-12.7%
This company
18.4%
Market median
-169% vs market
2018
2021
Net profit margin
-1189000.0%
This company
8.1%
Market median
-14679112% vs market
2018
2021
Asset turnover
-0.02×
This company
1.12×
Market median
-102% vs market
2018
2021
Debt / equity
0.21×
This company
0.62×
Market median
+66% vs market
2018
2021
Annual reports & filings
Annual report 2021
Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
View
PDF
Annual report 2019
Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
View
PDF
Annual report 2018
Filed via CVR / Virk · Period 2018-06-27 – 2018-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Trophic ApS
Company
100.0%
100.0%
2018
Mads Kristian Dalsgaard
Individual
100.0%
100.0%
2021
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Inflection Pharma Consulting ApS also hold positions in
0
other companies.
Person
Role here
Other companies